Seres Therapeutics (MCRB) Tops Q3 EPS by 24c, Beats on Revenues

Seres Therapeutics (NASDAQ: MCRB) reported Q3 EPS of ($0.17), $0.24 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $23 million versus the consensus estimate of $16 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
• Delta Air Lines stock climbs on earnings beat and strong guidance
• Occidental Petroleum releases Q2 2026 earnings considerations